KRAS Exon 2 Mutation (Q27908371)

From Wikidata

Jump to navigation Jump to search

genetic variant

EXON 2 MUTATION

Language	Label	Description	Also known as
English	KRAS Exon 2 Mutation	genetic variant	EXON 2 MUTATION

Statements

missense mutation

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/75

human chromosome 12

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/75

25398208

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/75

25398329

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/75

biological variant of

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/75

positive therapeutic predictor for

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/8367

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

determination method

CIViC evidence level B

CIViC 1-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Regorafenib in metastatic colorectal cancer.

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/87

Regorafenib in metastatic colorectal cancer.

negative therapeutic predictor for

medical condition treated

pancreatic carcinoma

statement disputed by

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/916

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/250

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

determination method

CIViC evidence level A

CIViC 5-star trust rating

medical condition treated

colorectal cancer

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/993

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

erlotinib / gemcitabine combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

pancreatic cancer

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1219

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy

negative prognostic predictor for

pancreatic carcinoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/917

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

determination method

CIViC evidence level B

CIViC 2-star trust rating

statement disputed by

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4052

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

statement disputed by

PIK3CA mutation is predictive of poor survival in patients with colorectal cancer

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2361

PIK3CA mutation is predictive of poor survival in patients with colorectal cancer

Identifiers

CIViC variant ID

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/75

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27908371&oldid=2014797535"